Results 301 to 310 of about 271,187 (352)
Some of the next articles are maybe not open access.
Current Opinion in Rheumatology, 2001
Methotrexate and leflunomide are both effective drugs in the treatment of patients with rheumatoid arthritis. Methotrexate has been available for many years, whereas leflunomide is a relatively new drug. Several large trials describing its efficacy and safety in comparison with both sulfasalazine and methotrexate and with placebo have been published ...
Laan, R.F.J.M. +2 more
openaire +4 more sources
Methotrexate and leflunomide are both effective drugs in the treatment of patients with rheumatoid arthritis. Methotrexate has been available for many years, whereas leflunomide is a relatively new drug. Several large trials describing its efficacy and safety in comparison with both sulfasalazine and methotrexate and with placebo have been published ...
Laan, R.F.J.M. +2 more
openaire +4 more sources
Pharmacokinetics of Methotrexate and 7-Hydroxy-Methotrexate After Methotrexate Infusions
Cancer Drug Delivery, 1987Methotrexate was administered by IV infusion, 2g (1.19 +/- 0.05 g/m2) over 24 hours, to a homogeneous group of patients undergoing treatment for breast cancer. Three courses were given at three week intervals. Methotrexate and 7-hydroxy-methotrexate plasma and urine pharmacokinetics were investigated. The average terminal half-lives of methotrexate and
S Just +4 more
openaire +3 more sources
Archives of Dermatology, 1967
Methotrexate is used for psoriasis by the majority of teaching services of dermatology in the United States. Three modes of administration were compared: small daily doses by mouth in interrupted schedules, single large weekly oral doses, and parenteral doses.
Harry L. Arnold +3 more
openaire +3 more sources
Methotrexate is used for psoriasis by the majority of teaching services of dermatology in the United States. Three modes of administration were compared: small daily doses by mouth in interrupted schedules, single large weekly oral doses, and parenteral doses.
Harry L. Arnold +3 more
openaire +3 more sources
Clinical and Experimental Dermatology, 1996
Methotrexate is an effective antipsoriatic agent and has been widely used to treat severe psoriasis since the 1960s. It is especially useful in acute generalized pustular psoriasis, psoriatic erythroderma, psoriatic arthritis and for extensive chronic plaque psoriasis in patients who are inadequately controlled by topical therapy alone.
M. J. Boffa, R.J.G. Chalmers
openaire +3 more sources
Methotrexate is an effective antipsoriatic agent and has been widely used to treat severe psoriasis since the 1960s. It is especially useful in acute generalized pustular psoriasis, psoriatic erythroderma, psoriatic arthritis and for extensive chronic plaque psoriasis in patients who are inadequately controlled by topical therapy alone.
M. J. Boffa, R.J.G. Chalmers
openaire +3 more sources
Dermatologic Therapy, 2007
Methotrexate is a folic acid analog pioneered for use in inflammatory diseases by dermatologists, and used successfully for over 40 years for a wide variety of cutaneous diseases. In addition to its antiproliferative properties, methotrexate has other more recently recognized anti-inflammatory properties related to its effects on adenosine.
Melissa I Costner, Carolyn A. Bangert
openaire +3 more sources
Methotrexate is a folic acid analog pioneered for use in inflammatory diseases by dermatologists, and used successfully for over 40 years for a wide variety of cutaneous diseases. In addition to its antiproliferative properties, methotrexate has other more recently recognized anti-inflammatory properties related to its effects on adenosine.
Melissa I Costner, Carolyn A. Bangert
openaire +3 more sources
The pharmacology of methotrexate
Expert Opinion on Pharmacotherapy, 2001Ectopic pregnancy (EP) is a major cause of maternal morbidity and mortality. The treatment of this condition is primarily surgical, but medical management in selected cases is safe, effective, cost-effective and eliminates the morbidity of surgery.
Christos Coutifaris +2 more
openaire +3 more sources
JAMA: The Journal of the American Medical Association, 1969
To the Editor.— The editorial ( 212 : 314, 1970) on psoriasis, methotrexate, and cirrhosis presents a cogent and balanced approach to the treatment of a patient with a long-term and recurrent problem. We feel that one statement ("... indications are expanding to include milder degrees of involvement where only cosmetic inconvenience exists") may be ...
openaire +3 more sources
To the Editor.— The editorial ( 212 : 314, 1970) on psoriasis, methotrexate, and cirrhosis presents a cogent and balanced approach to the treatment of a patient with a long-term and recurrent problem. We feel that one statement ("... indications are expanding to include milder degrees of involvement where only cosmetic inconvenience exists") may be ...
openaire +3 more sources
International Journal of Radiation Oncology*Biology*Physics, 1978
INTRODUCTION Methotrexate is an anatlogue of aminopterin which was first used in the treatment of acute leukaemia in 1947. However, because of its better therapeutic index, the closely related amethopterin superseded aminopterin and was marketed as Methotrexate.
openaire +3 more sources
INTRODUCTION Methotrexate is an anatlogue of aminopterin which was first used in the treatment of acute leukaemia in 1947. However, because of its better therapeutic index, the closely related amethopterin superseded aminopterin and was marketed as Methotrexate.
openaire +3 more sources
Journal of Allergy and Clinical Immunology, 1991
Recent trials of low-dosage methotrexate in chronic steroid-dependent asthma have engendered considerable interest and debate. It is still too early to say whether the variable sterold-sparlng effects In the reports to date will be found In other controlled studies underway.
openaire +3 more sources
Recent trials of low-dosage methotrexate in chronic steroid-dependent asthma have engendered considerable interest and debate. It is still too early to say whether the variable sterold-sparlng effects In the reports to date will be found In other controlled studies underway.
openaire +3 more sources
Pharmacogenetics of methotrexate
Pharmacogenomics, 2004Methotrexate (MTX) has proven efficient in the treatment of a number of malignancies, as well as non-malignant disorders characterized by a rapid cellular growth. Yet some patients might develop resistance, while others could have toxic side effects. MTX achieves its cytotoxicity through the inhibition of folate-dependent enzymes, suggesting that the ...
Maja Krajinovic, Albert Moghrabi
openaire +3 more sources